Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Organogenesis Holdings Inc. (NASDAQ:ORGO) is one of the best pharmaceutical stocks on our list.

TheFly reported on May 8 that BTIG downgraded ORGO to Neutral from Buy in a post–first-quarter update, with the price target withdrawn. The revised view reflects a slower-than-expected recovery in the Advanced Wound Care segment, with uncertainty around the timing of improvement. The report highlights that several market headwinds have weighed on the category, including reduced clarity in demand trends, lower utilization levels, and a shift among physicians toward simpler wound treatment options instead of more advanced dressings.

In a separate move, earlier on April 28, Organogenesis Holdings Inc. (NASDAQ:ORGO) completed the full rolling submission of its Biologics License Application to the U.S. FDA for ReNu, a cryopreserved amniotic suspension allograft intended for treating symptomatic knee osteoarthritis.

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

The filing process began in December 2025, when non-clinical sections were submitted first. With the latest step, the company has now delivered the remaining clinical data package along with chemistry, manufacturing, and controls documentation, finalizing the complete application package for regulatory review.

Organogenesis Holdings Inc. (NASDAQ:ORGO) is a regenerative medicine company that develops and commercializes tissue engineering and cell therapy products for advanced wound care and surgical applications, aiming to improve healing and patient outcomes.

While we acknowledge the risk and potential of ORGO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ORGO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1